Skip to main content
. Author manuscript; available in PMC: 2024 Jul 23.
Published in final edited form as: FASEB J. 2023 Mar;37(3):e22825. doi: 10.1096/fj.202201972RR

FIGURE 4.

FIGURE 4

(A) STZ/HFD mice exhibit hepatic fibrosis which is reduced by the eNAMPT-neutralizing ALT-100 mAb. In normal liver (Murine normal), Sirius Red only stained the wall of central vein and portal tract without staining around hepatocytes. In NAFLD murine models (Murine STZ/HFD), fibrosis shown by Sirius Red stain progressed to pericentral perihepatocellular area as often observed in human NAFLD liver. Treatment with ALT-100 significantly prevented pericellular fibrosis (Murine STZ/HFD + mAb). (B) Quantitative measures of the severity of fibrosis by Sirius red staining positive area were significantly reduced in IP ALT-100 mAb-treated NAFLD mice compared to disease control NAFLD mice treated with IP IgG (p < .05) (bar—20 μm).